PDCD1 and neoplasm: Immune checkpoint inhibitors (ICIs), which target immunosuppressive receptors such as CTLA-4 and PD-1 to improve the cytotoxicity and proliferative potential of tumor-infiltrating lymphocytes (TILs), are among the most effective immunotherapeutics [36].